

23 **Abstract**

24 **Background.** The neuropeptide oxytocin is proposed as a promising therapy for social
25 dysfunction by modulating amygdala-mediated social-emotional behavior. Although
26 clinical trials report some benefits of chronic treatment it is unclear whether efficacy
27 may be influenced by dose frequency or genotype.

28 **Methods.** In a randomized, double blind, placebo-controlled pharmaco-fMRI trial (150
29 male subjects) we investigated acute and different chronic (every day or on alternate
30 days for 5 days) intranasal oxytocin (24IU) effects and oxytocin receptor
31 genotype-mediated treatment sensitivity on amygdala responses to face emotions. We
32 also investigated similar effects on resting state functional connectivity between the
33 amygdala and prefrontal cortex.

34 **Results.** A single dose of oxytocin reduced amygdala responses to all face emotions
35 but for threatening (fear and anger) and happy faces this effect was abolished after daily
36 doses for 5 days but maintained by doses given every other day. The latter dose regime
37 also enhanced associated anxious-arousal attenuation for fear faces. Oxytocin effects
38 on reducing amygdala responses to face emotions only occurred in AA homozygotes of
39 rs53576 and A carriers of rs2254298. The effects of oxytocin on resting state functional
40 connectivity were not influenced by either dose-frequency or receptor genotype.

41 **Conclusions.** Infrequent chronic oxytocin administration may be therapeutically most
42 efficient and its anxiolytic neural and behavioral actions are highly genotype-dependent
43 in males.

45 **Introduction**

46 Intranasal oxytocin (OT) has been proposed as novel treatment to attenuate social
47 dysfunctions and anxiety in autism spectrum disorder, social anxiety and
48 schizophrenia (Kendrick et al., 2017; Meyer-Lindenberg et al., 2011; Young and
49 Barrett, 2015) as well as an augmentative strategy to facilitate fear extinction
50 (Eckstein et al., 2015) and working memory performance (Zhao et al., 2018).
51 Following an initial landmark study in humans demonstrating that OT reduces
52 amygdala responses to threatening (fear and angry) face stimuli (Kirsch et al., 2005),
53 subsequent preclinical research has consistently reported that its effects on amygdala
54 function (attenuated fear reactivity and increased amygdala-prefrontal intrinsic
55 connectivity - Domes et al., 2007; Eckstein et al., 2017; Kendrick et al., 2017;
56 Meyer-Lindenberg et al., 2011; Quintana et al., 2016; Spengler et al., 2017; Sripada et
57 al., 2013; Wang et al., 2017) may represent its primary therapeutic-relevant neural
58 mechanism of action.

59 The proposed neural mechanisms of OT have been established using acute single
60 dose administration protocols, with a dose-response study demonstrating 24
61 International Units (IU) as optimal for reducing amygdala responses to fear stimuli
62 using conventional intranasal spray devices (Spengler et al., 2017). To date however,
63 no human studies have demonstrated whether chronic treatment protocols can produce
64 enhanced functional effects and initial clinical trials using chronic (twice daily)
65 administration over periods of a week or longer have reported inconsistent, or at best

66 modest therapeutic efficacy on social-emotional dysfunctions (Guastella et al., 2015;
67 Halverson et al., 2019; Jarskog et al., 2017; Kendrick et al., 2017; Watanabe et al.,
68 2015; Yamasue et al., 2018).

69 G-protein-coupled neuropeptide receptors typically exhibit internalization
70 following even a relatively short period of constant exposure to their target peptides
71 and cannot subsequently respond (desensitized) until they are recycled back the
72 surface of the cell membrane (Pierce et al., 2002; Lohse and Hofmann, 2015).
73 Growing evidence from both in vitro and animal studies suggest there may be
74 extensive internalization and subsequent desensitization of OT receptors (OXTR)
75 following repeated OT administration (Smith et al., 2006; Stoop, 2012). In terms of
76 neural OXTR receptors those in the amygdala may be particularly susceptible to
77 desensitization (Terenzi and Ingram, 2005) and this region critically mediates many of
78 the effects of intranasal OT on social cognition and anxiety (Kendrick et al., 2017).
79 Moreover, rodent models have reported that in contrast to single doses, chronic
80 administration of OT can actually produce social impairment (Bales et al., 2013; Du
81 et al., 2017; Huang et al., 2014) in the context of reduced receptor expression in the
82 amygdala and nucleus accumbens (Du et al., 2017). Furthermore, an initial study
83 reported that chronic versus single administration of OT results in divergent
84 neurochemical changes in both the rodent and human frontal cortex (Benner et al.,
85 2018), emphasizing high translational relevance of the preclinical animal models for
86 clinical trials employing chronic treatment protocols. Thus, empirically evaluated

87 optimal treatment protocols for chronic intranasal OT administration in humans are
88 urgently needed to determine its therapeutic potential.

89 A further unresolved issue is that different OT receptor (OXTR) genotypes have
90 been associated with social behaviors and may influence sensitivity of behavioral and
91 neural responses to intranasal OT. In particular, OXTR polymorphisms rs53576 and
92 rs2254298 have been associated with autism (Cataldo et al., 2018), deficits in social
93 and emotional processing and anxiety (Jurek and Neumann, 2018; Parker et al., 2014;
94 Yang et al., 2017) and individual variations in behavioral and neural responses to
95 intranasal OT (Chen et al., 2015; Feng et al., 2015). Indeed, variants of rs2254298
96 may represent a trans-diagnostic biomarker for social dysfunctions (Brüne, 2012). It is
97 therefore imperative to establish whether OXTR polymorphisms could influence
98 sensitivity to effects of intranasal OT.

99 While single doses of OT can produce numerous functional effects, two of key
100 importance are attenuated amygdala responses to face emotions, particularly fear, and
101 increased resting state functional connectivity between the amygdala and prefrontal
102 cortex (Domes et al., 2007; Eckstein et al., 2017; Kirsch et al., 2005; Koch et al., 2016;
103 Quintana et al., 2016; Spengler et al., 2017; Sripada et al., 2013). While most task
104 studies have focused on the effects of OT on amygdala responses to fear faces using a
105 variety of different task paradigms some studies have reported valence independent
106 effects of OT (Domes et al., 2007; Koch et al., 2016; Quintana et al., 2016). Both
107 these task and resting state neural markers have been primarily associated with

108 attenuated anxiety in terms of reduced responses to social threat and enhanced
109 top-down control of emotion (Zhao et al., 2019), although effects of OT on the
110 amygdala may influence a range of social cognition domains (Kendrick et al., 2017;
111 Meyer-Lindenberg et al., 2011; Young and Barrett, 2015).

112 To help determine optimal treatment protocols for chronic intranasal OT
113 administration the current pre-registered double-blind, randomized between subject
114 placebo (PLC)-controlled pharmacological neuroimaging trial therefore aimed to
115 replicate previous findings for effects of a single dose of OT (24IU) on reduced
116 amygdala responses to fear or other face emotions (Domes et al., 2007; Kirsch et al.,
117 2005; Koch et al., 2016; Quintana et al., 2016; Spengler et al., 2017; Wang et al.,
118 2017) in a large sample at the whole brain level and on increasing resting-state
119 functional connectivity between the amygdala and prefrontal cortex (Eckstein et al.,
120 2017; Sripada et al., 2013). Next, the primary outcome of the trial was to establish
121 whether different repeat dosing protocols (daily, OT₅ group, or every other day, OT₃
122 group, for 5 days) modulate amygdala-centered neural and behavioral responses and
123 resting state functional connectivity. As a secondary outcome, we further aimed to
124 establish if effects of OT on primary outcome measures were influenced by OXTR
125 genotype, focusing on the rs53576 and rs2254298 polymorphisms most frequently
126 associated with social function and individual variations in intranasal OT sensitivity.

127 **Material and Methods**

128 The main study objectives were to investigate both the effects of acute (single dose)
129 and repeated doses (daily or every other day for 5 days) of 24IU OT versus PLC on
130 two primary outcomes: (1) amygdala and behavioral responses to face emotions
131 (particularly fear faces) and (2) resting state functional connectivity between the
132 amygdala and frontal cortex. We investigated modulatory influences of OXTR
133 rs53576 and rs2254298 polymorphisms on the sensitivity to intranasal OT as a
134 secondary outcome.

135 **Participants**

136 A total of 150, right-handed healthy adult male subjects were enrolled according to
137 common inclusion and exclusion criteria for human OT-administration studies (see
138 **SI**). Given that methods for estimating power for whole brain task-based fMRI
139 analyses are limited (Poldrack et al., 2017), subject number was initially chosen on
140 the basis of recent large-scale studies investigating dose effects of OT (Spengler et al.,
141 2017 n = 111 males; Lieberz et al., 2019, 90 females). A priori power estimates for
142 behavioral analyses were calculated using Webpower (Zhang and Yuan, 2018) giving
143 a range of 60-80% power for ANOVA main and interaction effects and post-hoc tests.
144 For full details see SI. Calculating power for fMRI experiments is more problematic
145 and likely to be much lower, although since the amygdala was our only pre-registered
146 ROI of interest, and the majority of fMRI post-hoc analyses used a single amygdala
147 ROI, this avoids the problem of significantly reduced power when undirected whole
148 brain analyses are performed (see Cremers et al., 2017). The current chosen sample

149 size is also comparable to the previous largest fMRI studies investigating task-related
150 effects of OT (Spengler et al., 2017; Lieberz et al., 2019). Three subjects failed to
151 meet inclusion criteria (were currently taking medications) and 9 subjects were
152 excluded due to failure to complete the study or excessive head movement (see **Fig.**
153 **S1**). Subjects were randomly (computer-generated randomization) assigned to
154 repeated intranasal treatment (single daily dose on five consecutive days) of (1)
155 placebo (PLC; $n = 46$, $M \pm SD$, 22.46 ± 2.3 years), (2) oxytocin (OT₅; $n = 49$, $M \pm SD$,
156 21.78 ± 2.3 years), or interleaved OT and PLC (OT on days 1, 3, 5, PLC on days 2, 4;
157 OT₃; $n = 43$, $M \pm SD$, 21.02 ± 2.0 years) (see **SI**). To ensure compliance all subjects
158 were supervised during self-administration of all nasal sprays. Groups did not differ
159 on a number of potential confounders (see **SI** and **Table S4**). The study was approved
160 by the local ethics committee (Institutional Review Board, University of Electronic
161 Science and Technology of China) and subjects provided written informed consent.
162 The study was in accordance with the latest revision of the Declaration of Helsinki,
163 pre-registered at Clinical Trials.gov (NCT03610919 -
164 <https://clinicaltrials.gov/ct2/show/NCT03610919>) and in line with recommendations
165 for trials in psychological experiments (Guidi et al., 2018) (see **Fig. S1** for Consort
166 flow diagram). Subjects received 500 RMB monetary compensation for participation.

167 **Experimental procedures**

168 The study employed a double-blind, randomized, placebo-controlled, between-subject
169 design. The OT and PLC sprays used in the 3 groups were supplied by Sichuan Meike

170 Pharmaceutical Co. Ltd, Sichuan, China in identical dispenser bottles containing
171 identical ingredients (glycerine and sodium chloride) other than OT. In line with
172 recommended guidelines experiments started 45 minutes after intranasal
173 administration (Guastella et al., 2013). Recent studies have confirmed that intranasal
174 OT enters the brain (Lee et al 2018), increases cerebrospinal fluid and blood
175 concentrations (Striepens et al., 2013) and produces activity changes in brain regions
176 expressing OXTRs in humans at around 45 minutes after administration (Paloyelis et
177 al., 2016; Quintana et al 2019). In post-treatment interviews on days 1 and 5 subjects
178 could not identify better than chance whether they had received OT or PLC ($\chi^2 < 0.1$,
179 $p > 0.2$, **Table S4**). For OXTR genotyping subjects provided buccal swaps on the 1st
180 day for analysis of OXTR rs2254298, rs53576 SNPs (see **SI** and (Montag et al.,
181 2017)).

182 For the implicit face-emotion processing task 208 grayscale facial stimuli
183 displaying happy, neutral, angry or fearful facial expressions (n = 26 per category,
184 50% female) were used (two different stimulus sets - see **SI** for details).

185 **Primary outcomes and analysis plan**

186 Face emotion-related amygdala responses were assessed using the event-related
187 implicit face processing fMRI paradigm on treatment days 1 and 5. Intrinsic amygdala
188 connectivity was assessed by means of resting state fMRI assessments before the
189 task-paradigm. Valence, arousal and intensity ratings (scale: 1-9) for the facial stimuli
190 were collected immediately after MRI acquisition as additional behavioral outcomes

191 (further details see **SI**). In line with the main aim of the study changes in amygdala
192 face emotion reactivity and amygdala intrinsic connectivity between the 1st and 5th
193 day served as primary outcome measures. Changes in valence, arousal and intensity
194 ratings for the different face emotions represented an associated behavioral outcome
195 measure.

196 **Imaging acquisition and analysis**

197 Blood oxygenation level-dependent contrast functional images were acquired using
198 standard sequences on a 3T GE MR750 system. High resolution T1-weighted
199 structural MRI data were acquired on both 1st and 5th days to improve normalization.
200 MRI data was preprocessed using validated procedures in SPM12 (Friston et al., 1994)
201 (Statistical Parametric Mapping; <http://www.fil.ion.ucl.ac.uk/spm>) and Data
202 Processing Assistant or Resting-State fMRI (Yan, 2010) (DPARSFA;
203 <http://rfmri.org/DPARSF>) (for details see **SI**). First level General Linear Models
204 (GLM) for the task-related fMRI data included separate regressors for the four
205 emotional conditions, gender identity rating period and 6 movement parameters and
206 appropriate contrasts were subjected to a second level random effects analysis.

207 **Primary outcomes: The effects of OT on amygdala and behavioral face emotion** 208 **reactivity and intrinsic connectivity**

209 Differences in amygdala and behavioral responses to face emotions were examined
210 using mixed ANOVAs with treatment group (PLC, OT₃, OT₅) as between-subject and
211 time point (1st and 5th days) and face emotion (angry, fear, happy and neutral) as

212 within-subject factors. Dependent variables were extracted target region amygdala
213 responses using the template of left and right amygdala masks from the Brainnetome
214 atlas (Fan et al., 2016) to faces (parameter estimates extracted using Marsbar,
215 <http://marsbar.sourceforge.net>) and valence, intensity and arousal ratings. Post-hoc
216 comparisons explored significant interactions for amygdala and behavioral ratings.
217 Associations between amygdala responses and behavioral ratings were assessed using
218 Pearson correlation.

219 Differences in resting state amygdala functional connectivity were determined
220 using a voxel-wise seed-to-whole-brain ANOVA as implemented in the SPM flexible
221 factorial design with treatment (PLC, OT₃, OT₅) as between-subject and time point
222 (1st and 5th days) as within-subject factors and amygdala connectivity maps as
223 dependent variable. (See data analysis flow chart in **SI**)

224 **Secondary outcome measures: influence of OXTR genotype**

225 For rs2254298 subjects were divided into A carriers (AA and AG) and A non-carriers
226 (GG) and rs53576 into G carriers (GG and GA) and G non-carriers (AA). To explore
227 effects of genotype as a secondary outcome measure, OXTR group was included as an
228 additional between-subject factor in the corresponding ANOVAs and amygdala
229 reactivity to face emotions, amygdala-prefrontal cortex intrinsic functional
230 connectivity and behavior rating response served as dependent variables.

231 **Control for treatment effects on brain structure**

232 To control for potential confounding effects of single- and repeated
233 OT-administration on brain structure, a voxel-based morphometry (VBM) analysis
234 was conducted on the T1-weighted images acquired on both testing days using
235 SPM12 standard procedures (Ashburner, 2007; Ashburner and Friston, 2005)(see **SI**).

236 **Thresholding and statistical implementation**

237 In line with our regional hypothesis the analysis of the implicit emotional face task
238 focused on the amygdala. To account for the complex design of the trial we employed
239 two analytic approaches: (1) A region of interest analysis (ROI) on the extracted beta
240 estimates from atlas-based masks for the left and right amygdala (Brainnetome Atlas,
241 Fan et al., 2016) respectively. To this end the extracted estimates were subjected to
242 three-way ANOVAs (treatment \times time point \times face emotion) examining effects on the
243 left and right amygdala separately. The p-value for the analysis was adopted to
244 $p < 0.025$ (Bonferroni corrected multiple comparison $0.05/2$). (2) To facilitate a more
245 specific localization of the effects and to determine a more specific seed mask for the
246 seed-to-whole brain resting state functional connectivity analysis a voxel-wise small
247 volume corrected (SVC) analysis for the entire bilateral amygdala was additionally
248 employed. To this end a peak-level Family-wise error (FWE) small volume correction
249 was applied to a single mask encompassing the bilateral amygdala as provided in the
250 Brainnetome Atlas (Fan et al., 2016) (total volume of the mask, 4572.27mm^3) (FWE p
251 $< .05$). For the seed-to-whole brain resting state data analysis a whole-brain
252 cluster-based FWE-correction with an initial cluster forming threshold of $p < .001$ and

253 FWE $p < .05$ was employed. Behavioral and neural (extracted parameter estimates)
254 indices were further analyzed using SPSS 22.0 with appropriate ANOVA models and
255 Bonferroni corrected post-hoc tests. $P < 0.05$ two-tailed was considered significant.
256 Partial eta squared (η^2_p) and Cohen's d were computed for behavioral results as
257 measures of effect size and SPSS outlier analysis was used to confirm the absence of
258 statistical outliers. Full details of the post-hoc and correlation analyses are provided in
259 the SI (Tables S7 – S11).

260 **Results**

261 **Primary outcome measure: ROI analysis of acute and repeated doses on**

262 **OT-evoked changes in amygdala responses to face emotions**

263 Examination of the extracted parameter estimates from the amygdala (a priori ROI
264 approach in accordance with trial pre-registration) revealed a significant three-way
265 ANOVA for the right amygdala ($F_{(6,405)}=2.563$; $p<0.019$), but not the left amygdala
266 ($F_{(6,405)}=1.860$; $p=0.087$). Post-hoc analyses on the extracted beta values from the
267 right amygdala mask on the 1st day revealed that both OT groups compared to PLC
268 exhibited a suppression of right amygdala reactivity (fear: $ps < 0.015$, angry: $ps <$
269 0.016 ; happy: $ps < 0.041$; neutral: $ps < 0.017$). Analysis on the 5th day revealed that
270 the OT₃ group exhibited a suppression of right amygdala reactivity to fear and angry
271 faces relative to both the PLC (fear: $p = 0.003$, angry: $p = 0.008$) and OT₅ groups (fear:
272 $p = 0.021$; angry: $p = 0.082$) but the OT₅ group did not ($ps > 0.315$, relative to PLC
273 group). The OT₃ group also exhibited reduced right amygdala reactivity to happy

274 faces on the 5th day compared with the PLC group ($p = 0.028$) but there was no
275 significant difference between OT₃ and OT₅ groups ($p = 0.272$). There were no
276 significant effects of OT on the 5th day for neutral faces ($p > 0.203$, although OT₃ vs
277 PLC was marginal, $p = 0.052$). While amygdala reactivity to fear faces did not differ
278 in the PLC group between days 1 and 5 ($p = 0.356$), its reduction in the OT₃ group on
279 day 5 was equivalent to day 1 ($p = 0.538$) whereas in the OT₅ group the reduction on
280 day 5 was significantly less than on day 1 ($p = 0.035$). Amygdala reactivity to angry
281 faces decreased significantly more in the OT₃ group on day 5 relative to day 1 ($p =$
282 0.006), although it also did so in the PLC group for both angry ($p = 0.007$) and neutral
283 ($p = 0.028$) (**Fig. 1b-e**).

284 **Primary outcome measure: behavioral rating analysis of acute and** 285 **repeated doses to face emotions**

286 Mixed ANOVAs on the behavioral data revealed a significant main effect of
287 treatment group on arousal ratings (arousal: $F_{2, 135} = 5.06$, $p = 0.008$, $\eta^2_p = 0.07$) due to
288 ratings generally being lower in the OT₃ group. There was also a marginal significant
289 treatment group x time point x face emotion interaction effect for arousal ($F_{6,405} =$
290 1.83 , $p = 0.093$, $\eta^2_p = 0.03$) and a significant one for intensity ($F_{6,405} = 3.327$, $p =$
291 0.004 , $\eta^2_p = 0.05$). Post-hoc analysis showed that intensity ratings were significantly
292 reduced for fear faces in the OT₃ group on the 5th day (fear: $p = 0.004$ versus PLC, $d =$
293 0.62 , 95% CI, -1.299 to -0.247, $p = 0.088$ versus OT₅, $d = 0.33$, 95% CI, -0.968 to
294 0.068). Exploratory post-hoc analysis of arousal ratings revealed a similar reduction

295 to fear faces on day 5 ($p = 0.001$ versus PLC, $d = 0.77$, 95% CI, -1.544 to -0.420, $p =$
296 0.033 versus OT₅, $d = 0.42$, 95% CI, -1.158 to -0.051). Arousal ratings to fear faces
297 were also decreased in the OT₃ group on the 1st day compared to the PLC group but
298 not the OT₅ group (arousal: $p = 0.015$ versus PLC, $d = 0.60$, 95% CI, 0.129 to 1.175,
299 $p = 0.355$ versus OT₅, 95% CI, -0.268 to 0.744). Arousal and intensity ratings to
300 angry faces were reduced on day 5 compared with day 1 in the OT₃ (arousal: $p =$
301 0.001, $d = 0.30$, 95% CI, 0.164 to 0.619, intensity: $p = 0.001$, $d = 0.32$, 95% CI, 0.173
302 to 0.641) and OT₅ groups (arousal: $p = 0.023$, $d = 0.19$, 95% CI, 0.032 to 0.461,
303 intensity: $p = 0.006$, $d = 0.26$, 95% CI, 0.088 to 0.526). There were no significant
304 differences for angry, neutral and happy faces between OT and PLC groups on the 1st
305 day (p s > 0.194, although OT₅ vs PLC was marginal, $p = 0.051$ for neutral faces) and 5th
306 day (p s > 0.671, although OT₃ vs PLC $p = 0.053$ was marginal for angry faces). There
307 was however a significant group difference between OT₃ and OT₅ on the 1st and 5th
308 day for happy and neutral faces (p s < 0.007) (**Fig.2**). While there was a significant
309 3-way interaction for valence ratings ($F_{6, 405} = 2.63$, $p = 0.016$, $\eta^2_p = 0.04$), post-hoc
310 analysis revealed no significant differences between OT and PLC groups on the 1st
311 (p s > 0.200) or 5th days (p s > 0.173).

312 The whole brain voxel based morphometry analysis revealed no significant
313 effects of acute or repeated doses of OT on gray matter volumes.

314 **Associations between amygdala responses and behavioral ratings to emotional**
315 **faces**

316 Associations between right amygdala activation (extracted parameter estimates from
317 the right amygdala mask as provided by the Brainnetome atlas) and emotional arousal
318 and intensity scores to fear faces were observed in the PLC group on the 1st day
319 (arousal: $r = 0.295$, $p = 0.023$; intensity: $r = 0.455$, $p = 0.001$) demonstrating that
320 greater amygdala activation in response to fear faces was associated with increased
321 anxiety. This association was absent in both OT groups on the 1st day (arousal: OT₃, r
322 $= 0.041$, $p = 0.398$; OT₅, $r = 0.050$, $p = 0.366$; intensity: OT₃, $r = 0.098$, $p = 0.265$;
323 OT₅, $r = 0.164$, $p = 0.130$). A similar trend occurred on the 5th day (arousal: PLC, $r =$
324 0.306 , $p = 0.019$; OT₃, $r = -0.011$, $p = 0.471$; OT₅ group, $r = -0.120$, $p = 0.206$;
325 intensity: PLC, $r = 0.212$, $p = 0.079$; OT₃, $r = -0.108$, $p = 0.246$; OT₅ group, $r = -0.043$,
326 $p = 0.385$) (**Fig.3**). There was a similar relationship with responses to angry faces for
327 intensity but not arousal ratings in the PLC group on the 1st day. (arousal: $r = 0.107$, p
328 $= 0.240$; intensity: $r = 0.297$, $p = 0.023$). No associations were found for responses to
329 neutral or happy faces.

330 **Primary outcome measure: effects of acute and repeated oxytocin doses on**
331 **resting-state functional connectivity**

332 To facilitate a more precise localization of the coordinates of amygdala for the resting
333 state analysis a voxel-wise mixed ANOVA with treatment group (PLC, OT₃, OT₅) as
334 between-subject, time point (1st and 5th days) and face emotion (happy, neutral, angry
335 and fear) as within-subject factor was computed on the task-based data. This analysis
336 revealed a significant three-way interaction effect in the right amygdala after small

337 volume correction for the bilateral mask encompassing the entire amygdala ($k = 7$,
338 $p_{FWE} = 0.021$, $F_{6,405} = 4.47$, peak MNI co-ordinate: $x=18$, $y=-7$, $z=-16$) (**Fig.4a**)
339 confirming the findings from the ROI analysis which revealed a significant interaction
340 effect for the right amygdala only. An amygdala seed-to-whole brain fMRI
341 resting-state analysis employing this region as seed (6 radius sphere centered at $x=18$,
342 $y=-7$, $z=-16$) by mixed-effect ANOVA revealed a main effect of treatment (OT₃, OT₅
343 and PLC) on amygdala functional coupling with the anterior prefrontal cortex (peak
344 MNI coordinate $x = -3$, $y = 53$, $z = -19$, $F_{2, 135} = 16.55$, $p_{FWE} = 0.001$, $k = 88$) (see Fig.
345 4a) but no treatment group x time point interaction. Right amygdala intrinsic
346 connectivity with the prefrontal cortex was stronger in both the OT₃ ($k = 74$, $p_{FWE} =$
347 0.014 , $x = -3$, $y = 53$, $z = -19$) and OT₅ groups ($k = 127$, $p_{FWE} = 0.001$, $x = -3$, $y = 53$,
348 $z = -19$) relative to PLC. The OT₃ and OT₅ groups did not differ significantly on the
349 1st ($p = 0.147$) or 5th ($p = 0.107$) days (see Fig. 4b). Correlation analysis revealed no
350 significant association between resting state and amygdala task-related changes
351 ($r = -0.08$, $p = 0.59$ in PLC group) or behavioral ratings of emotional faces
352 ($-0.085 < r_s < 0.055$, $p_s > 0.57$).

353 **Secondary outcome measure: Associations between OT-effects and OXTR**
354 **genotype**

355 The number of G-carriers and G-non-carriers of rs53576 and A-carriers and
356 A-non-carriers of rs2254298 did not differ between the three groups and both SNPs
357 satisfied Hardy Weinberg Equilibrium (see **Tables S2 and S3**). A four-way mixed

358 ANOVA with treatment group and genotype as between- and time point and face
359 emotion as within-subject factors revealed significant treatment x genotype
360 interactions for both rs2254298 and rs53576 (rs 2254298: $F_{2, 105} = 3.17$, $p = 0.046$,
361 rs53576: $F_{2, 105} = 3.23$, $p = 0.044$) for amygdala responses to emotional faces,
362 although they would not survive a Bonferroni correction for 4 genotypes (i.e.
363 $p < 0.0125$). Post-hoc analysis showed that reduced amygdala reactivity to emotional
364 faces in both OT groups occurred in A-carriers of rs2254298 ($ps < 0.009$) but not
365 A-non-carriers ($ps > 0.587$) and G-non-carriers of rs 53576 ($ps < 0.002$) but not
366 G-carriers ($ps > 0.196$) (see Fig. 5a-b). For behavioral ratings there were significant
367 treatment group x genotype interactions for both arousal and intensity ratings for
368 rs2254298 (arousal: $F_{2, 105} = 6.60$, $p = 0.002$, $\eta^2_p = 0.11$; intensity: $F_{2, 105} = 3.85$, $p =$
369 0.024 , $\eta^2_p = 0.07$). Post-hoc analysis showed that decreased ratings for faces in the
370 OT₃ group only occurred in A-carriers (arousal: versus PLC: $p = 0.002$, $d = 4.68$, 95%
371 CI, 0.363 to 1.524 and OT₅ $p < 0.001$, $d = 6.56$, 95% CI, 0.743 to 1.904; intensity:
372 PLC: $p = 0.021$, $d = 3.40$, 95% CI, 0.109 to 1.301; OT₅: $p = 0.003$, $d = 4.40$, 95% CI,
373 0.314 to 1.507). No significant main or interaction effects involving treatment and
374 genotype were found for resting state functional connectivity between amygdala and
375 prefrontal cortex (rs 2254298 all $ps > 0.123$; rs53576 all $ps > 0.566$).

376 Discussion

377 Overall, our findings validate OT-reductions in amygdala responses to face emotions
378 and associated emotional intensity and arousal ratings for fear faces, together with

379 increased resting state functional connectivity between the amygdala and prefrontal
380 cortex as robust markers for its putative therapeutic mechanisms of action. While,
381 these task-dependent and resting-state effects of OT show a different sensitivity to
382 repeated intranasal doses and OXTR genotype our findings indicate that to achieve
383 maximal effects of chronic treatment on neural and behavioral responses to face
384 emotion stimuli and resting-state changes the optimal protocol may be to administer
385 24IU doses every other day rather than daily.

386 Our findings are highly consistent with preclinical animal models demonstrating
387 OXTR desensitization following repeated doses of OT in some brain regions (Terenzi
388 and Ingram, 2005; Smith et al., 2005; Stoop, 2012) and that chronic administration
389 can reduce brain OXTR expression (Du et al., 2017) and alter patterns of
390 neurochemical release (Benner et al., 2018). Importantly, chronic doses of OT in
391 rodents fail to produce anxiolytic effects normally seen with single doses (Du et al.,
392 2017) which mirrors our present observations. The apparent long-lasting
393 desensitization effects of daily OT administration on amygdala responses to
394 threatening and happy faces may be contributed to by dose magnitude and so possibly
395 lower daily doses might be less problematic. We also observed some evidence for
396 reduced amygdala and behavioral responses to repeated emotional face presentations
397 in the PLC group in line with previous observations (Fischer et al., 2003; Wright et al.,
398 2001), even though different sets of face stimuli were used at the two time-points.
399 This may have served to reduce time-dependent effects of OT to some extent.

400 The amygdala is one of the main neural substrates mediating OT's functional
401 effects and its attenuation of reactivity to threatening stimuli is considered as a
402 putative primary therapeutic mechanism of action (see Jurek and Neumann, 2018;
403 Kendrick et al., 2017; Neumann and Slattery, 2016). However, in the current study we
404 demonstrated similar effects of OT in reducing right amygdala responses to all
405 emotional faces, although desensitization effects were only significant for threatening
406 (fear and anger) and happy faces. While some previous studies have found effects of
407 OT only for fear faces (Spengler et al., 2017) or for fear and angry ones (Kirsch et al.,
408 2005), our current findings are in agreement with a number of others reporting that it
409 can reduce amygdala responses to both positive and negative (Domes et al., 2007) or
410 all face emotions (Koch et al., 2016; Quintana et al., 2016). A possible explanation for
411 these differences could be that studies, including our own, using presentation
412 strategies where subjects are not directly required to identify or discriminate between
413 face emotions (Domes et al., 2007; Koch et al., 2016; Quintana et al., 2016) have
414 tended to report valence-independent results. Importantly however, only the
415 magnitude of amygdala responses to fear faces was positively associated with arousal
416 and intensity ratings in the PLC group and OT exerted an anxiolytic action by both
417 reducing these ratings and abolishing their correlation with amygdala activation.
418 Dysregulations in amygdala and behavioral responses to threatening stimuli have been
419 observed across major psychiatric disorders, particularly those characterized by
420 marked social impairments and anxiety (Hennessey et al., 2018; Neumann and
421 Slattery, 2016). There was some evidence that behavioral anxiolytic effects of OT

422 were greater after repeated compared to single doses in the group receiving OT every
423 other day for angry faces but not in terms of amygdala responses. Possibly the short 5
424 day period for OT-treatment was not sufficient to demonstrate robust enhancement
425 effects of repeated doses and time-dependent enhancement effects of longer duration
426 treatment need to be investigated in studies on clinical populations.

427 A major finding from our secondary outcome measure is that OT's attenuations
428 of neural and behavioral responses to face emotions are highly dependent on OXTR
429 genotype. Only G non-carriers of rs53576 and A-carriers of rs2254298 showed
430 significant reductions in amygdala responses to face emotions under OT although
431 only A-carriers of rs2254298 showed evidence for significant reductions in arousal
432 and intensity ratings. A-carriers of both SNPs have frequently been associated with
433 social dysfunction in autism and social anxiety disorders (Cataldo et al., 2018; Jurek
434 and Neumann, 2018). A recent haplotype-based analysis of OXTR SNPs including
435 rs53576 and rs2254298 also indicated an association with sensitivity to OT-effects on
436 face recognition (Chen et al., 2015).

437 Interestingly, task-related and intrinsic network changes produced by OT showed
438 a strikingly different sensitivity to repeated doses and OXTR genotype and there were
439 no associations between resting state connectivity and either amygdala or behavioral
440 responses to face emotions. However, for the resting state effects of OT there was no
441 advantage of giving OT daily as opposed to every other day. Intrinsic networks may
442 therefore be less sensitive to the effects of repeated OT administration or OXTR

443 genotype than those engaged by external social emotional stimuli, although arguably
444 the effects of OT on neural processing during actual processing of social cues should
445 be of greatest therapeutic relevance.

446 There are several limitations in the current study. Firstly, we only included male
447 subjects to increase relevance to potential therapeutic use in autism and to avoid
448 menstrual cycle effects. There is however increasing evidence for sex-dependent
449 effects of OT, notably for amygdala responses (Gao et al., 2016; Jurek and Neumann,
450 2018; Lieberz et al., 2019; Luo et al., 2017) and also for rs53576 (Feng et al., 2015).
451 Thus, females may show different responses to repeated doses of OT and associations
452 with receptor genotype. Secondly, for the genotype analysis, subject numbers are
453 relatively low for establishing robust associations. While treatment x genotype
454 interactions only passed Bonferroni correction for arousal ratings, post-hoc tests for
455 both behavioral and amygdala effects were highly significant. . The AA allele of
456 rs53576 also occurs more frequently in Asian and Caucasian populations (Butovskaya
457 et al., 2016). Finally, we only examined the effects of one dose and time course for
458 the effects of OT and there may be dose-dependent and temporal variations. The 24IU
459 dose and 45 min post-treatment time course used are the same as in many previous
460 studies demonstrating both task and resting-state effects of OT (Kendrick et al., 2017)
461 and maximal effects on reduced amygdala responses to fear faces occur with a 24IU
462 dose from 45-75 min (Spengler et al., 2017). However, higher doses may produce
463 different effects (Spengler et al., 2017) and a recent regional cerebral blood flow

464 study has reported reduced resting amygdala activity at shorter time points following
465 40IU intranasal OT (Martins et al., 2020).

466 In conclusion, the current study provides the first evidence for an important
467 influence of OT dose frequency and receptor genotype on its modulation of neural
468 and behavioral responses to emotional faces in healthy human subjects. Dose
469 frequency therefore requires further empirical evaluation in patient populations given
470 that it can critically determine treatment efficacy in clinical trials employing chronic
471 administration.

472 **Acknowledgement:** We thank the reviewers and editor for their comments and
473 suggestions for improving the manuscript. **Funding:** This project was supported by
474 National Natural Science Foundation of China (NSFC) grant numbers 31530032
475 (KMK) and 91632117 (BB). **Author contributions:** JK and KMK designed the
476 experiment. JK, YZ and CS carried out the experiment. JK, KMK, CM, FZ and BB
477 analyzed the experiment and JK, KMK, CM and BB wrote the paper. All authors
478 contributed to the conception of the study and approved the paper. **Competing**
479 **interests:** The authors declare that they have no competing interests.

480

481

482

483

484 **References**

- 485 Bales, K. L., Perkeybile, A. M., Conley, O. G., Lee, M. H., Guoynes, C. D., Downing,
486 G. M., ... & Mendoza, S. P. (2013). Chronic intranasal oxytocin causes
487 long-term impairments in partner preference formation in male prairie voles.
488 *Biological Psychiatry*, 74(3), 180-188.
- 489 Benner, S., Aoki, Y., Watanabe, T., Endo, N., Abe, O., Kuroda, M., ... & Kasai, K.
490 (2018). Neurochemical evidence for differential effects of acute and repeated
491 oxytocin administration. *Molecular Psychiatry*, 1-11.
- 492 Brüne, M. (2012). Does the oxytocin receptor polymorphism (rs2254298) confer
493 'vulnerability' for psychopathology or 'differential susceptibility'? Insights
494 from evolution. *BMC Medicine*, 10(1), 38.
- 495 Butovskaya, P. R., Lazebny, O. E., Sukhodolskaya, E. M., Vasiliev, V. A., Dronova,
496 D. A., Fedenok, J. N., ... & Butovskaya, M. L. (2016). Polymorphisms of two
497 loci at the oxytocin receptor gene in populations of Africa, Asia and South
498 Europe. *BMC Genetics*, 17(1), 17.
- 499 Cataldo, I., Azhari, A., & Esposito, G. (2018). A review of oxytocin and
500 arginine-vasopressin receptors and their modulation of autism spectrum
501 disorder. *Frontiers in Molecular Neuroscience*, 11, 27.
- 502 Chen, F. S., Kumsta, R., Dvorak, F., Domes, G., Yim, O. S., Ebstein, R. P., &
503 Heinrichs, M. (2015). Genetic modulation of oxytocin sensitivity: a
504 pharmacogenetic approach. *Translational Psychiatry*, 5(10), e664-e664.

- 505 Cremers, H. R., Wager, T. D., & Yarkoni, T. (2017). The relation between statistical
506 power and inference in fMRI. *PloS one*, 12(11), e0184923.
- 507 Domes, G., Heinrichs, M., Gl äscher, J., Büchel, C., Braus, D. F., & Herpertz, S. C.
508 (2007). Oxytocin attenuates amygdala responses to emotional faces regardless
509 of valence. *Biological Psychiatry*, 62(10), 1187-1190.
- 510 Du, P., He, Z., Cai, Z., Hao, X., Dong, N., Yuan, W., ... & Tai, F. (2017). Chronic
511 central oxytocin infusion impairs sociability in mandarin voles. *Pharmacology*
512 *Biochemistry and Behavior*, 161, 38-46.
- 513 Eckstein, M., Becker, B., Scheele, D., Scholz, C., Preckel, K., Schlaepfer, T. E., ... &
514 Hurlemann, R. (2015). Oxytocin facilitates the extinction of conditioned fear
515 in humans. *Biological Psychiatry*, 78(3), 194-202.
- 516 Eckstein, M., Markett, S., Kendrick, K. M., Ditzen, B., Liu, F., Hurlemann, R., &
517 Becker, B. (2017). Oxytocin differentially alters resting state functional
518 connectivity between amygdala subregions and emotional control networks:
519 Inverse correlation with depressive traits. *Neuroimage*, 149, 458-467.
- 520 Eklund, A., Nichols, T. E., & Knutsson, H. (2016). Cluster failure: Why fMRI
521 inferences for spatial extent have inflated false-positive rates. *Proceedings of*
522 *the National Academy of Sciences*, 113(28), 7900-7905.
- 523 Fan, L., Li, H., Zhuo, J., Zhang, Y., Wang, J., Chen, L., ... & Fox, P. T. (2016). The
524 human brainnetome atlas: a new brain atlas based on connectional architecture.
525 *Cerebral Cortex*, 26(8), 3508-3526.

- 526 Feng, C., Lori, A., Waldman, I. D., Binder, E. B., Haroon, E., & Rilling, J. K. (2015).
527 A common oxytocin receptor gene (OXTR) polymorphism modulates
528 intranasal oxytocin effects on the neural response to social cooperation in
529 humans. *Genes, Brain and Behavior*, 14(7), 516-525.
- 530 Fischer, H., Wright, C.I., Whalen, P.J., McInerney, S.C., Shine, L.M., & Rauch, S.L.
531 (2003). Brain habituation during repeated exposure to fearful and neutral faces.
532 *Brain Research Bulletin* 59(5), 387-392.
- 533 Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. P., Frith, C. D., & Frackowiak,
534 R. S. (1994). Statistical parametric maps in functional imaging: a general
535 linear approach. *Human Brain Mapping*, 2(4), 189-210.
- 536 Gao, S., Becker, B., Luo, L., Geng, Y., Zhao, W., Yin, Y., ... & Kendrick, K.M.
537 (2016). Oxytocin, the peptide that bonds the sexes also divides them.
538 *Proceedings of the National Academy of Sciences*, 113(27), 7650-7654.
- 539 Guastella, A. J., Gray, K. M., Rinehart, N. J., Alvares, G. A., Tonge, B. J., Hickie, I.
540 B., ... & Einfeld, S. L. (2015). The effects of a course of intranasal oxytocin on
541 social behaviors in youth diagnosed with autism spectrum disorders: a
542 randomized controlled trial. *Journal of Child Psychology and Psychiatry*, 56(4),
543 444-452.
- 544 Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger,
545 H. M., ... & Banati, R. B. (2013). Recommendations for the standardisation of
546 oxytocin nasal administration and guidelines for its reporting in human
547 research. *Psychoneuroendocrinology*, 38(5), 612-625.

- 548 Guidi, J., Brakemeier, E. L., Bockting, C. L., Cosci, F., Cuijpers, P., Jarrett, R. B., ...
549 & Rief, W. (2018). Methodological recommendations for trials of
550 psychological interventions. *Psychotherapy and Psychosomatics*, 87(5),
551 276-284.
- 552 Halverson, T., Jarskog, L. F., Pedersen, C., & Penn, D. (2019). Effects of oxytocin on
553 empathy, introspective accuracy, and social symptoms in schizophrenia: A
554 12-week twice-daily randomized controlled trial. *Schizophrenia Research*, 204,
555 178-182.
- 556 Hennessey, T., Andari, E., & Rainnie, D. G. (2018). RDoC-based categorization of
557 amygdala functions and its implications in autism. *Neuroscience &*
558 *Biobehavioral Reviews*, 90, 115-129.
- 559 Huang, H., Michetti, C., Busnelli, M., Manago, F., Sannino, S., Scheggia, D., ... &
560 Scattoni, M. L. (2014). Chronic and acute intranasal oxytocin produce
561 divergent social effects in mice. *Neuropsychopharmacology*, 39(5),
562 1102-1114.
- 563 Jarskog, L. F., Pedersen, C. A., Johnson, J. L., Hamer, R. M., Rau, S. W., Elliott, T.,
564 & Penn, D. L. (2017). A 12-week randomized controlled trial of twice-daily
565 intranasal oxytocin for social cognitive deficits in people with schizophrenia.
566 *Schizophrenia Research*, 185, 88-95.
- 567 Jurek, B., & Neumann, I. D. (2018). The oxytocin receptor: from intracellular
568 signaling to behavior. *Physiological Reviews*, 98(3), 1805-1908.

- 569 Kendrick, K. M., Guastella, A. J., & Becker, B. (2017). Overview of human oxytocin
570 research. In Behavioral Pharmacology of Neuropeptides: Oxytocin (pp.
571 321-348). Springer, Cham. pp. 321–348.
- 572 Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., ... &
573 Meyer-Lindenberg, A. (2005). Oxytocin modulates neural circuitry for social
574 cognition and fear in humans. *Journal of Neuroscience*, 25(49), 11489-11493.
- 575 Koch, S.B.J., van Zuiden, M., Nawijn, L., Frijling, J.L., Veltman, D.J. (2016).
576 Intranasal oxytocin administration dampens amygdala reactivity towards
577 emotional faces in male and female PTSD patients.
578 *Neuropsychopharmacology*, 41, 1495-1504.
- 579 Lieberz, J., Scheele, D., Spengler, F. B., Matheisen, T., Schneider, L., Stoffel-Wagner,
580 B., ... & Hurlemann, R. (2019). Kinetics of oxytocin effects on amygdala and
581 striatal reactivity vary between women and men. *Neuropsychopharmacology*,
582 1-7.
- 583 Lee, M. R., Scheidweiler, K. B., Diao, X. X., Akhlaghi, F., Cummins, A., Huestis, M.
584 A., ... & Averbeck, B. B. (2018). Oxytocin by intranasal and intravenous
585 routes reaches the cerebrospinal fluid in rhesus macaques: determination using
586 a novel oxytocin assay. *Molecular Psychiatry*, 23(1), 115-122.
- 587 Lohse, M. J., & Hofmann, K. P. (2015). Spatial and Temporal Aspects of Signaling
588 by G-Protein–Coupled Receptors. *Molecular Pharmacology*, 88(3), 572-578.

- 589 Luo, L., Becker, B., Geng, Y., Zhao, Z., Gao, S., Zhao, W., ... & Hu, J. (2017).
590 Sex-dependent neural effect of oxytocin during subliminal processing of
591 negative emotion faces. *Neuroimage*, 162, 127-137.
- 592 Martins, D.A., Mazibuko, N, Zelaya, F., Vasilakopoulou, S., Loveridge, J., Oates,
593 U., ... & Paloyelis, Y. (2020). Effects of route of administration on
594 oxytocin-induced changes in regional cerebral blood flow in humans. *Nature*
595 *Communications* doi: 10.1038/s41467-020-14845-5
- 596 Meyer-Lindenberg, A., Domes, G., Kirsch, P., & Heinrichs, M. (2011). Oxytocin and
597 vasopressin in the human brain: social neuropeptides for translational
598 medicine. *Nature Reviews Neuroscience*, 12(9), 524-538.
- 599 Montag, C., Sindermann, C., Melchers, M., Jung, S., Luo, R., Becker, B., ... &
600 Kendrick, K. M. (2017). A functional polymorphism of the OXTR gene is
601 associated with autistic traits in Caucasian and Asian populations. *American*
602 *Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, 174(8),
603 808-816.
- 604 Mueller, K., Lepsien, J., Möller, H. E., & Lohmann, G. (2017). Commentary: Cluster
605 failure: Why fMRI inferences for spatial extent have inflated false-positive
606 rates. *Frontiers in Human Neuroscience*, 11, 345.
- 607 Neumann, I. D., & Slattery, D. A. (2016). Oxytocin in general anxiety and social fear:
608 a translational approach. *Biological Psychiatry*, 79(3), 213-221.

- 609 Paloyelis, Y., Doyle, O. M., Zelaya, F. O., Maltezos, S., Williams, S. C., Fotopoulou,
610 A., & Howard, M. A. (2016). A spatiotemporal profile of in vivo cerebral
611 blood flow changes following intranasal oxytocin in humans. *Biological*
612 *Psychiatry*, 79(8), 693-705.
- 613 Parker, K. J., Garner, J. P., Libove, R. A., Hyde, S. A., Hornbeak, K. B., Carson, D.
614 S., ... & Hardan, A. Y. (2014). Plasma oxytocin concentrations and OXTR
615 polymorphisms predict social impairments in children with and without autism
616 spectrum disorder. *Proceedings of the National Academy of Sciences*, 111(33),
617 12258-12263.
- 618 Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). Seven-transmembrane
619 receptors. *Nature Reviews Molecular Cell Biology*, 3(9), 639-650.
- 620 Poldrack, R. A., Baker, C. I., Durnez, J., Gorgolewski, K. J., Matthews, P. M.,
621 Munafò, M. R., ... & Yarkoni, T. (2017). Scanning the horizon: towards
622 transparent and reproducible neuroimaging research. *Nature Reviews*
623 *Neuroscience*, 18(2), 115.
- 624 Quintana, D. S., Rokicki, J., van der Meer, D., Alnæs, D., Kaufmann, T.,
625 Córdova-Palomera, A., ... & Westlye, L. T. (2019). Oxytocin pathway gene
626 networks in the human brain. *Nature Communications*, 10(1), 1-12.
- 627 Quintana, D.S., Westlye, L.T., Alnaes, D., Rustan, Ø.G., Kaufmann, T.,...&
628 Andreassen, O.A. (2016). Low dose intranasal oxytocin delivered with Breath
629 Powered device dampens amygdala response to emotional stimuli: A

630 peripheral effect-controlled within-subjects randomized dose-response fMRI
631 trial. *Psychoneuroendocrinology*, 69, 180-188.

632 Russell, J. A. (2018). 50 years of advances in neuroendocrinology. *Brain and*
633 *Neuroscience Advances*, 2, 1-20.

634 Smith, M. P., Ayad, V. J., Mundell, S. J., McArdle, C. A., Kelly, E., & López Bernal,
635 A. (2006). Internalization and desensitization of the oxytocin receptor is
636 inhibited by Dynamin and clathrin mutants in human embryonic kidney 293
637 cells. *Molecular Endocrinology*, 20(2), 379-388.

638 Spengler, F. B., Schultz, J., Scheele, D., Essel, M., Maier, W., Heinrichs, M., &
639 Hurlemann, R. (2017). Kinetics and dose dependency of intranasal oxytocin
640 effects on amygdala reactivity. *Biological Psychiatry*, 82(12), 885-894.

641 Sripada, C. S., Phan, K. L., Labuschagne, I., Welsh, R., Nathan, P. J., & Wood, A. G.
642 (2013). Oxytocin enhances resting-state connectivity between amygdala and
643 medial frontal cortex. *International Journal of Neuropsychopharmacology*,
644 16(2), 255-260.


645 Stoop, R. (2012). Neuromodulation by oxytocin and vasopressin. *Neuron*, 76(1),
646 142-159.

647 Striepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., &
648 Hurlemann, R. (2013). Elevated cerebrospinal fluid and blood concentrations
649 of oxytocin following its intranasal administration in humans. *Scientific*
650 *Reports*, 3, 3440.

- 651 Terenzi, M. G., & Ingram, C. D. (2005). Oxytocin-induced excitation of neurones in
652 the rat central and medial amygdaloid nuclei. *Neuroscience*, 134(1), 345-354.
- 653 Wang, D., Yan, X., Li, M., & Ma, Y. (2017). Neural substrates underlying the effects
654 of oxytocin: a quantitative meta-analysis of pharmaco-imaging studies. *Social
655 Cognitive and Affective Neuroscience*, 12(10), 1565-1573.
- 656 Watanabe, T., Kuroda, M., Kuwabara, H., Aoki, Y., Iwashiro, N., Tatsunobu, N., ... &
657 Kasai, K. (2015). Clinical and neural effects of six-week administration of
658 oxytocin on core symptoms of autism. *Brain*, 138(11), 3400-3412.
- 659 Wright, C. I., Fischer, H., Whalen, P. J., McInerney, S. C., Shin, L. M., Rauch, S. L.
660 (2001). Differential prefrontal cortex and amygdala habituation to repeatedly
661 presented emotional stimuli. *Neuroreport*, 12,379–383.
- 662 Yamasue, H., Okada, T., Munosue, T., Kuroda, M., Fujioka, T., Uno, Y., ... &
663 Yoshimura, Y. (2018). Effect of intranasal oxytocin on the core social
664 symptoms of autism spectrum disorder: a randomized clinical trial. *Molecular
665 Psychiatry*, 1-10.
- 666 Chao-Gan, Y., & Yu-Feng, Z. (2010). DPARSF: a MATLAB toolbox for “pipeline”
667 data analysis of resting-state fMRI. *Frontiers in Systems Neuroscience*, 4.
- 668 Yang, S., Dong, X., Guo, X., Han, Y., Song, H., Gao, L., ... & Zhang, X. (2017).
669 Serum oxytocin levels and an oxytocin receptor gene polymorphism
670 (rs2254298) indicate social deficits in children and adolescents with autism
671 spectrum disorders. *Frontiers in Neuroscience*, 11, 221.

- 672 Young, L. J., & Barrett, C. E. (2015). Can oxytocin treat autism? *Science*, 347(6224),
673 825-826.
- 674 Zhang, Z., & Yuan, K.H. (2018). Practical Statistical Power Analysis Using
675 Webpower and R (Eds). *Granger, IN: ISDSA Press.*
- 676 Zhao, W., Becker, B., Yao, S., Ma, X., Kou, J., & Kendrick, K. M. (2019). Oxytocin
677 enhancement of the placebo effect may be a novel therapy for working
678 memory impairments. *Psychotherapy and Psychosomatics*, 88(2), 125-126.
- 679 Zhao, Z., Yao, S., Li, K., Sindermann, C., Zhou, F., Zhao, W., ... & Becker, B. (2019).
680 Real-time functional connectivity-informed neurofeedback of
681 amygdala-frontal pathways reduces anxiety. *Psychotherapy and*
682 *Psychosomatics*, 88(1), 5-15.
- 683
- 684

685 **Figure Legends**



686


687 **Fig.1** The effect of intranasal oxytocin (OT) treatment on neural responses to faces. (a)

688 The mask of right amygdala from the Brainnetome atlas (Fan et al., 2016)(b-e) Post

689 hoc analysis on extracted parameter estimates from the right amygdala mask for all

690 face emotion categories on the 1st and 5th days.# p < 0.1, * p < 0.05, ** p < 0.01,

691 two-tailed. Bars depict standard errors.



692

693 **Fig.2** The effects of oxytocin (OT) on arousal and intensity ratings for face emotions.

694 (a) OT decreased arousal and intensity ratings of fear faces on both the 1st and the 5th

695 days of treatment in the group receiving OT on alternate days (OT₃) compared with


696 placebo (PLC) and ratings were significantly reduced on day 5 relative to day 1. The

697 group receiving OT every day (OT₅) did not show significant effects on either day 1

698 or 5. No effects of OT on ratings for (b) anger, (c) happy and (d) happy face emotions.

699 # $p < 0.1$, * $p < 0.05$, ** $p < 0.01$ two-tailed, Bars depict standard errors.

700



701

702 **Fig.3** Associations between intensity and arousal ratings of fear faces and amygdala

703 activation in the placebo (PLC) and two OT treatment groups (OT₃ and OT) on days 1

704 and 5. The magnitude of right amygdala (from the Brainnetome atlas) responses was


705 positively correlated with arousal and intensity ratings in the PLC group on day 1 but

706 not in the OT groups. There was a similar trend on day 5. *p< 0.05. **p<0.01

707 (Pearson Correlation).

708

709



710

711 **Fig.4** The effects of oxytocin (OT) on resting state functional connectivity (a)

712 schematic visualization of the identified functional pathway between the right

713 amygdala and anterior prefrontal cortex (replicating Eckstein et al., 2017). (b) Seed to

714 whole-brain analysis of functional connectivity (FC, seed region right amygdala, 6mm

715 sphere, x=18, y=-7, z=-16) revealed significantly increased functional connectivity

716 between right amygdala and anterior prefrontal cortex ($p_{FWE} = 0.039$, x = -36, y = 59, z

717 = -7) in both OT treatment groups (OT₃ and OT₅) on both, days 1 and 5 relative to

718 placebo (PLC). Line graphs depict the extracted parameter estimates from right

719 amygdala connectivity with anterior prefrontal cortex (M ± SE). * $p < 0.05$, ** $p <$


720 0.01 two-tailed. Bars indicate standard errors.

721

722

723

724



725

726 **Fig.5** Influence of oxytocin (OT) receptor genotype on the effects of intranasal OT on
 727 right amygdala and behavioral responses to face emotions (n = 111 subjects). (a) for
 728 rs 53576 only G-non carriers (i.e. AA) showed reduced amygdala responses to faces
 729 (PLC, n_{G+}=15, n_{G-}=21; OT₃, n_{G+}=17, n_{G-}=24; OT₅, n_{G+}=20, n_{G-}=14); (b) for
 730 rs2254298 only A-carriers (i.e. AA and AG) in the groups with intranasal oxytocin
 731 (OT) treatment showed reduced amygdala responses to faces (PLC, n_{A+}=20, n_{A-}=16;
 732 OT₃, n_{A+}=23, n_{A-}=18; OT₅, n_{A+}=20, n_{A-}=14) ; (c) for rs2254298 only A-carriers (i.e.
 733 AA and AG) in the groups with intranasal oxytocin (OT) treatment showed reduced
 734 emotional arousal ratings ** p < 0.01, two-tailed t-test (Bonferroni corrected
 735 significance threshold of p = 0.0125). Bars indicate standard errors.